Cargando…
Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
The role played by glycoprotein (GP) IIb/IIIa inhibitors has continuously evolved from the initial introduction in mid 90 s until the most recent guidelines for treating acute coronary syndromes, and competed with a wider use of ADP inhibitors and novel anticoagulant drugs, to the extent that they s...
Autores principales: | Iannetta, Loredana, Puddu, Paolo Emilio, Cuturello, Domenico, Saladini, Angela, Pellicano, Mariano, Schiariti, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358181/ https://www.ncbi.nlm.nih.gov/pubmed/28348696 http://dx.doi.org/10.4021/cr251w |
Ejemplares similares
-
GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin
por: Schiariti, Michele, et al.
Publicado: (2010) -
Age- and Gender-Normalized Coronary Incidence and Mortality Risks in Primary and Secondary Prevention
por: Puddu, Paolo Emilio, et al.
Publicado: (2012) -
Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021) -
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
por: Suwaidi, Jassim Al, et al.
Publicado: (2001) -
The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)